DDInter174 DDInter1676
Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Belinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Belinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denosumab
Belinostat {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Belinostat {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Belinostat may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Belinostat may lead to a major life threatening interaction when taken with Leflunomide